Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome

European Respiratory Journal

Volumn 21, Issue 4, 2003, Pages 720-727

  Moloney, E D ^a   Evans, T W ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Acute respiratory distress syndrome; Pulmonary hypertension

Indexed keywords

ALMITRINE DIMESILATE; BOSENTAN; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; ISOPRENALINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OXYGEN; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1; PROSTANOID; SILDENAFIL; VASODILATOR AGENT;

BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG METABOLISM; DRUG SELECTIVITY; HISTOPATHOLOGY; HUMAN; HYPOTENSION; HYPOXEMIA; LUNG BLOOD VESSEL; LUNG EDEMA; LUNG EMBOLISM; LUNG INJURY; LUNG INTERSTITIUM; LUNG SHUNTING; LUNG VASOCONSTRICTION; METHEMOGLOBINEMIA; OXYGEN THERAPY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY DISTRESS; REVIEW; SURVIVAL; VASODILATATION;

EID: 0037386020     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00120102     Document Type: Review

References (93)

1. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-824.
2. Zapol WM, Snider MT. Pulmonary hypertension in severe acute respiratory failure. N Engl J Med 1977; 296: 476-480.
3. Tomashefski JF Jr, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983; 112: 112-126.
4. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138: 720-723.
5. Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317: 1565-1570.
6. Bone RC, Slotman G, Maunder R, et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest 1989; 96: 114-119.
7. Sloane PJ, Gee MH, Gottlieb JE, et al. A multicenter registry of patients with acute respiratory distress syndrome. Am Rev Respir Dis 1992; 146: 419-426.
8. Suchyta MR, Clemmer TP, Elliott CG, Orme JF Jr, Weaver LK. The adult respiratory distress syndrome. A report of survival and modifying factors. Chest 1992; 101: 1074-1079.
9. Sibbald WJ, Driedger AA. Right ventricular function in acute disease states: pathophysiologic considerations. Crit Care Med 1983; 11: 339-345.
10. Prewitt RM, McCarthy J, Wood LD. Treatment of acute low pressure pulmonary edema in dogs: relative effects of hydrostatic and oncotic pressure, nitroprusside, and positive end-expiratory pressure. J Clin Invest 1981; 67: 409-418.
11. Sibbald WJ, Paterson NA, Holliday RL, Anderson RA, Lobb TR, Duff JH. Pulmonary hypertension in sepsis: measurement by the pulmonary arterial diastolic-pulmonary wedge pressure gradient and the influence of passive and active factors. Chest 1978; 73: 583-591.
12. Schuster DP. ARDS: clinical lessons from the oleic acid model of acute lung injury. Am J Respir Crit Care Med 1994; 149: 245-260.
13. Gust R, McCarthy TJ, Kozlowski J, Stephenson AH, Schuster DP. Response to inhaled nitric oxide in acute lung injury depends on distribution of pulmonary blood flow prior to its administration. Am J Respir Crit Care Med 1999; 159: 563-570.
14. Dantzker DR, Brook CJ, Dehart P, Lynch JP, Weg JG. Ventilation-perfusion distributions in the adult respiratory distress syndrome. Am Rev Respir Dis 1979; 120: 1039-1052.
15. Melot C, Naeije R, Mois P, Hallemens R, Lejeune P, Jaspar N. Pulmonary vascular tone improves pulmonary gas exchange in the adult respiratory distress syndrome. Am Rev Respir Dis 1987; 136: 1232-1236.
16. Grant BJ, Davies EE, Jones HA, Hughes JM. Local regulation of pulmonary blood flow and ventilation-perfusion ratios in the coatimundi. J Appl Physiol 1976; 40: 216-228.
17. Melot C, Naeije R, Hallemans R, Lejeune P, Mols P. Hypoxic pulmonary vasoconstriction and pulmonary gas exchange in normal man. Respir Physiol 1987; 68: 11-27.
18. Brimioulle S, Lejeune P, Naeije R. Effects of hypoxic pulmonary vasoconstriction on pulmonary gas exchange. J Appl Physiol 1996; 81: 1535-1543.
19. Leeman M, Delcroix M, Vachiery JL, Melot C, Naeije R. Blunted hypoxic vasoconstriction in oleic acid lung injury: effects of cyclooxygenase inhibitors. J Appl Physiol 1992; 72: 251-258.
20. Archer SL, Weir EK, Reeve HL, Michelakis E. Molecular identification of O2 sensors and O2-sensitive potassium channels in the pulmonary circulation. Adv Exp Med Biol 2000; 475: 219-240.
21. Liu SF, Crawley DE, Barnes PJ, Evans TW. Endothelium-derived relaxing factor inhibits hypoxic pulmonary vasoconstriction in rats. Am Rev Respir Dis 1991; 143: 32-37.
22. Brimioulle S, Julien V, Gust R, Kozlowski JK, Naeije E, Schuster DP. Importance of hypoxic vasoconstriction in maintaining oxygenation during acute lung injury. Crit Care Med 2002; 30: 874-880.
23. Leeman M, Lejeune P, Closset J, Vachiery JL, Melot C, Naeije R. Nature of pulmonary hypertension in canine oleic acid pulmonary edema. J Appl Physiol 1990; 69: 293-298.
24. Repine JE. Scientific perspectives on adult respiratory distress syndrome. Lancet 1992; 339: 466-469.
25. Leeman M, Lejeune P, Hallemans R, Melot C, Naeije R. Effects of increased pulmonary vascular tone on gas exchange in canine oleic acid pulmonary edema. J Appl Physiol 1988; 65: 662-668.
26. Schulman LL, Lennon PF, Ratner SJ, Enson Y. Meclofenamate enhances blood oxygenation in acute oleic acid lung injury. J Appl Physiol 1988; 64: 710-718.
27. Leeman M, De Beyl VZ, Gilbert E, Melot C, Naeije R. Is nitric oxide released in oleic acid lung injury? J Appl Physiol 1993; 74: 650-654.
28. Esbenshade AM, Newman JH, Lams PM, Jolles PH, Brigham KL. Respiratory failure after endotoxin infusion in sheep: lung mechanics and lung fluid balance. J Appl Physiol 1982; 53: 967-976.
29. Doebber TW, Wu MS, Robbins JC, Choy BM, Chang MN, Shen TY. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. Biochem Biophys Res Commun 1985; 127: 799-808.
30. Christman BW, Lefferts PL, Blair IA, Snapper JR. Effect of platelet-activating factor antagonism on endotoxin-induced lung dysfunction in awake sheep. Am Rev Respir Dis 1990; 142: 1272-1278.
31. Petrak RA, Balk RA, Bone RC. Prostaglandins, cyclooxygenase inhibitors, and thromboxane synthase inhibitors in the pathogenesis of multiple systems organ failure. Crit Care Clin 1989; 5: 303-314.
32. Hinson JM, Hutchinson AA, Ogletree ML, Brigham KL, Snapper JR. Effect of granulocyte depletion on altered lung mechanics after endotoxemia in sheep. J Appl Physiol 1983; 55: 92-99.
33. Snapper JR, Hinson JM, Hutchinson AA, Lefferts PL, Ogletree ML, Brigham KL. Effects of platelet depletion on the unanaesthetized sheep's pulmonary response to endotoxemia. J Clin Invest 1984; 74: 1782-1791.
34. Winn R, Harlan J, Nadir B, Harker L, Hildebrandt J. Thromboxane A2 mediates lung vasoconstriction but not permeability after endotoxin. J Clin Invest 1983; 72: 911-918.
35. Begley CJ, Ogletree ML, Meyrick BO, Brigham KL. Modification of pulmonary responses to endotoxemia in awake sheep by steroidal and nonsteroidal anti-inflammatory agents. Am Rev Respir Dis 1984; 130: 1140-1146.
36. Leeman M, Boeynaems JM, Degaute JP, Vincent JL, Kahn RJ. Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome. Chest 1985; 87: 726-730.
37. Hetchman HB, Valeri CR, Shepro D. Role of humoral mediators in adult respiratory distress syndrome. Chest 1984; 86: 623-627.
38. Ogletree ML, Brigham KL. Effects of cyclooxygenase inhibitors on pulmonary vascular responses to endotoxin in unanesthetized sheep. Prostaglandins Leukot Med 1982; 8: 489-502.
39. Matthay MA, Eschenbacher WL, Goetzl EJ. Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with the adult respiratory distress syndrome. J Clin Immunol 1984; 4: 479-483.
40. Coggeshall JW, Christman BW, Lefferts PL, et al. Effect of inhibition of 5-lipoxygenase metabolism of arachidonic acid on response to endotoxemia in sheep. J Appl Physiol 1988; 65: 1351-1359.
41. Olson NC, Dobrowsky RT, Fleisher LN. Hydroxyeicosatetraenoic acids are increased in bronchoalveolar lavage fluid of endotoxemic pigs. Prostaglandins 1987; 34: 493-503.
42. Ahmed T, Wasserman MA, Muccitelli R, Tucker S, Gazeroglu H, Marchette B. Endotoxin-induced changes in pulmonary hemodynamics and respiratory mechanics. Role of lipoxygenase and cyclooxygenase products. Am Rev Respir Dis 1986; 134: 1149-1157.
43. Ahmed T, Weichman B, Wasserman MA, Muccitelli R, Tucker S, Marchette B. Prevention and reversal of endotoxin-induced pulmonary hypertension by a leukotriene antagonist. Eur Respir J 1988; 1: 145-152.
44. Gross D, Ben Dahan J, Landau EH, Krausz MM. Effect of leukotriene inhibitor LY-171883 on the pulmonary response to Escherichia coli endotoxemia. Crit Care Med 1990; 18: 190-197.
45. Beetens JR, Loots W, Somers Y, Coene MC, De Clerck F. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol 1986; 35: 883-891.
46. Slotman GJ, Burchard KW, D'Arezzo A, Gann DS. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma 1988; 28: 648-654.
47. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993; 21: 1635-1642.
48. Sinuff T, Cook DJ, Peterson JC, Fuller HD. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. J Crit Care 1999; 14: 1-6.
49. Network TA. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA 2000; 283: 1995-2002.
50. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
51. Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol 2001; 25: 104-110.
52. MacLean MR. Endothelin-1: a mediator of pulmonary hypertension? Pulm Pharmacol Ther 1998; 11: 125-132.
53. Woods M, Mitchell JA, Wood EG, et al. Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol 1999; 55: 902-909.
54. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
55. Druml W, Steltzer H, Waldhausl W, et al. Endothelin-1 in adult respiratory distress syndrome. Am Rev Respir Dis 1993; 148: 1169-1173.
56. Barth PJ, Knoch M, Muller E, Sangmeister C, Bittinger A. Morphometry of parenchymal and vascular alterations in ARDS after extracorporeal carbon dioxide removal therapy. Pathol Res Pract 1992; 188: 653-656.
57. Greene R, Zapol WM, Snider MT, et al. Early bedside detection of pulmonary vascular occlusion during acute respiratory failure. Am Rev Respir Dis 1981; 124: 593-601.
58. Leeman M. The pulmonary circulation in acute lung injury: a review of some recent advances. Intensive Care Med 1991; 17: 254-260.
59. Pierpont G, Hale KA, Franciosa JA, Cohn JN. Effects of vasodilators on pulmonary haemodynamics and gas exchange in left ventricular failure. Am Heart J 1980; 99: 208-216.
60. Melot C, Lejeune P, Leeman M, Moraine JJ, Naeije R. Prostaglandin E1 in the adult respiratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange. Am Rev Respir Dis 1989; 139: 106-110.
61. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
62. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273-277.
63. Wort SJ, Mitchell JA, Woods M, Evans TW, Warner TD. The prostacyclin-mimetic cicaprost inhibits endogenous endothelin-1 release from human pulmonary artery smooth muscle cells. J Cardiovasc Pharmacol 2000; 36: S410-S413.
64. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399-405.
65. Radermacher P, Huet Y, Pluskwa F, et al. Comparison of ketanserin and sodium nitroprusside in patients with severe ARDS. Anesthesiology 1988; 68: 152-157.
66. Zapol WM, Rimar S, Gillis N, Marletta M, Bosken CH. Nitric oxide and the lung. Am J Respir Crit Care Med 1994; 149: 1375-1380.
67. Dinh-Xuan AT, Brunet F, Dhainaut JF. The use, and misuse, of exogenous endothelial-derived vasodilators in acute respiratory failure. Intensive Care Med 1997; 23: 1110-1118.
68. Singh S, Evans TW. Nitric oxide, the biological mediator of the decade: fact or fiction? Eur Respir J 1997; 10: 699-707.
69. Brett SJ, Hansell DM, Evans TW. Clinical correlates in acute lung injury: response to inhaled nitric oxide. Chest 1998; 114: 1397-1404.
70. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2000-2012.
71. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83: 2038-2047.
72. Fratacci MD, Frostell CG, Chen TY, Wain JC, Robinson DR, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991; 75: 990-999.
73. Weitzberg E, Rudehill A, Alving K, Lundberg JM. Nitric oxide inhalation selectively attenuates pulmonary hypertension and arterial hypoxia in porcine endotoxin shock. Acta Physiol Scand 1991; 143: 51-52.
74. Ogura H, Saitoh D, Johnson AA, Mason AA, Pruitt BA, Cioffi WG. The effect of inhaled nitric oxide on pulmonary ventilation-perfusion matching following smoke inhalation injury. J Trauma 1994; 37: 893-898.
75. Ogura H, Cioffi WG, Offner PJ, Jordan BS, Johnson AA, Pruitt BA. Effect of inhaled nitric oxide on pulmonary function after sepsis in a swine model. Surgery 1994; 116: 313-321.
76. Sheridan BC, McIntyre RC, Meldrum DR, Fullerton DA. L-arginine prevents lung neutrophil accumulation and preserves pulmonary endothelial function after endotoxin. Am J Physiol 1998; 274: 337-342.
77. Shah NS, Nakayama DK, Jacob TD, et al. Efficacy of inhaled nitric oxide in oleic-acid induced acute lung injury. Crit Care Med 1997; 25: 153-158.
78. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase 2 trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998; 26: 15-23.
79. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med 1999; 25: 911-999.
80. Michael JR, Barton RG, Saffle JR, et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med 1998; 157: 1372-1380.
81. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998; 157: 1483-1488.
82. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153: 991-996.
83. Zwissler B, Kemming G, Habbler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154: 1671-1677.
84. Puybasset L, Stewart T, Rouby JJ, et al. Inhaled nitric oxide reverses the increase in pulmonary vascular resistance induced by permissive hypercapnia in patients with acute respiratory distress syndrome. Anesthesiology 1994; 80: 1254-1267.
85. Okanu Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997; 349: 1365.
86. Papazian L, Roch A, Bregeon F, et al. Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome. Am J Respir Crit Care Med 1999; 160: 473-479.
87. Papazian L, Bregeon F, Gaillat F, et al. Inhaled NO and almitriene bismesylate in patients with acute respiratory distress syndrome: effects of noradrenaline. Eur Respir J 1999; 14: 1283-1289.
88. Gallart L, Lu Q, Puybasset L, Umamaheswara Rao GS, Coriat P, Rouby JJ. Intravenous almitriene combined with inhaled nitric oxide for acute respiratory distress syndrome. The NO Almitriene Study Group. Am J Respir Crit Care Med 1998; 158: 1770-1777.
89. Melot C, Naeije R, Rothschild T, Mertens P, Mols P, Hallemens R. Improvement in ventilation-perfusion matching by almitriene in COPD. Chest 1983; 83: 528-533.
90. Reyes A, Roca J, Rodriguez-Roisin R, Torres A, Ussetti P, Wagner PD. Effect of almitriene on ventilation-perfusion distribution in adult respiratory distress syndrome. Am Rev Respir Dis 1988; 137: 1062-1067.
91. Wysocki M, Delclaux C, Roupie E, et al. Additive effect on gas exchange of inhaled nitric oxide and intravenous almitriene bismesylate in the adult respiratory distress syndrome. Intensive Care Med 1994; 20: 254-259.
92. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
93. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.